On 30 March 2022, the Authority communicated to the Commission its conclusion [EFSA Journal 2022;20(5):7296.] on whether oxamyl can be expected to meet the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009.
Recital 8, Regulation (EU) 2023/741
In forcesince 5 Apr 2023